Literature DB >> 19406987

KLRG1 signaling induces defective Akt (ser473) phosphorylation and proliferative dysfunction of highly differentiated CD8+ T cells.

Sian M Henson1, Ornella Franzese, Richard Macaulay, Valentina Libri, Rita I Azevedo, Sorena Kiani-Alikhan, Fiona J Plunkett, Joanne E Masters, Sarah Jackson, Stephen J Griffiths, Hans-Peter Pircher, Maria V D Soares, Arne N Akbar.   

Abstract

Highly differentiated CD8+CD28-CD27- T cells have short telomeres, defective telomerase activity, and reduced capacity for proliferation, indicating that they are close to replicative senescence. In addition, these cells express increased levels of the senescence-associated inhibitory receptor KLRG1 and have poor capacity for IL-2 synthesis and defective Akt (ser(473)) phosphorylation after activation. It is not known whether signaling via KLRG1 contributes to any of the attenuated differentiation-related functional changes in CD8+ T cells. To address this, we blocked KLRG1 signaling during T-cell receptor activation using antibodies against its major ligand, E-cadherin. This resulted in a significant enhancement of Akt (ser(473)) phosphorylation and T-cell receptor-induced proliferative activity of CD8+CD28-CD27- T cells. Furthermore, the increase of proliferation was directly linked to the Akt-mediated induction of cyclin D and E and reduction in the cyclin inhibitor p27 expression. In contrast, the reduced telomerase activity in highly differentiated CD8+CD28(-)CD27- T cells was not altered by KLRG1 blockade, indicating the involvement of other mechanisms. This is the first demonstration of a functional role for KLRG1 in primary human CD8+ T cells and highlights that certain functional defects that arise during progressive T-cell differentiation toward replicative senescence are maintained actively by inhibitory receptor signaling.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19406987     DOI: 10.1182/blood-2009-01-199588

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  111 in total

1.  IL-7Rαlow memory CD8+ T cells are significantly elevated in patients with systemic lupus erythematosus.

Authors:  Jung-Sik Kim; Bon-A Cho; Ji Hyun Sim; Kamini Shah; Connie M Woo; Eun Bong Lee; Dong-Sup Lee; Jae Seung Kang; Wang Jae Lee; Chung-Gyu Park; Joe Craft; Insoo Kang; Hang-Rae Kim
Journal:  Rheumatology (Oxford)       Date:  2012-06-01       Impact factor: 7.580

Review 2.  Once a killer, always a killer: from cytotoxic T cell to memory cell.

Authors:  Leo Lefrançois; Joshua J Obar
Journal:  Immunol Rev       Date:  2010-05       Impact factor: 12.988

3.  Increased numbers of preexisting memory CD8 T cells and decreased T-bet expression can restrain terminal differentiation of secondary effector and memory CD8 T cells.

Authors:  Nikhil S Joshi; Weiguo Cui; Claudia X Dominguez; Jonathan H Chen; Timothy W Hand; Susan M Kaech
Journal:  J Immunol       Date:  2011-09-19       Impact factor: 5.422

Review 4.  The immune system in the aging human.

Authors:  Paulina Dominika Rymkiewicz; Yi Xiong Heng; Anusha Vasudev; Anis Larbi
Journal:  Immunol Res       Date:  2012-09       Impact factor: 2.829

5.  Finding Balance: T cell Regulatory Receptor Expression during Aging.

Authors:  Mary M Cavanagh; Qian Qi; Cornelia M Weyand; Jörg J Goronzy
Journal:  Aging Dis       Date:  2011-10-28       Impact factor: 6.745

6.  Differential effects of STAT5 and PI3K/AKT signaling on effector and memory CD8 T-cell survival.

Authors:  Timothy W Hand; Weiguo Cui; Yong Woo Jung; Esen Sefik; Nikhil S Joshi; Anmol Chandele; Ying Liu; Susan M Kaech
Journal:  Proc Natl Acad Sci U S A       Date:  2010-09-07       Impact factor: 11.205

7.  Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy.

Authors:  Christian S Hinrichs; Zachary A Borman; Luca Gattinoni; Zhiya Yu; William R Burns; Jianping Huang; Christopher A Klebanoff; Laura A Johnson; Sid P Kerkar; Shicheng Yang; Pawel Muranski; Douglas C Palmer; Christopher D Scott; Richard A Morgan; Paul F Robbins; Steven A Rosenberg; Nicholas P Restifo
Journal:  Blood       Date:  2010-10-22       Impact factor: 22.113

Review 8.  Uncoupling T-cell expansion from effector differentiation in cell-based immunotherapy.

Authors:  Joseph G Crompton; Madhusudhanan Sukumar; Nicholas P Restifo
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

Review 9.  Sorting through subsets: which T-cell populations mediate highly effective adoptive immunotherapy?

Authors:  Christopher A Klebanoff; Luca Gattinoni; Nicholas P Restifo
Journal:  J Immunother       Date:  2012 Nov-Dec       Impact factor: 4.456

Review 10.  Memories that last forever: strategies for optimizing vaccine T-cell memory.

Authors:  Jeffrey D Ahlers; Igor M Belyakov
Journal:  Blood       Date:  2009-11-10       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.